This MS drug increases risk of hospitalisation Published: 27 August 2021 A new study has found that Ocrevus (ocrelizumab) slows disability progression and reduces relapse risk in people with multiple sclerosis (MS) but is also associated with higher hospitalisation risk in older people.  Most of the hospitalisations were from urinary